Aurinia Pharmaceuticals INC Schedule 13D activist filings

ILJIN SNT, ILJIN Steel, and ILJIN GLS, along with individuals Sae Kyoung Huh, Seoung Eun Huh, and Chin Kyu Huh, have filed an amendment to their Schedule 13D, reporting a decrease in their beneficial ownership of Aurinia Pharmaceuticals Inc. common shares to below 5%.

Tang Capital Management and Kevin Tang have increased their beneficial ownership in Aurinia Pharmaceuticals to 10.0%.

Kevin Tang, a significant beneficial owner, has been appointed Chief Executive Officer of Aurinia Pharmaceuticals Inc.

Tang Capital Management and affiliates have increased their beneficial ownership in Aurinia Pharmaceuticals Inc. to 9.2% through recent open market purchases totaling $26.3 million.

ILJIN SNT and Seoung Eun Huh reduce their beneficial ownership in Aurinia Pharmaceuticals, bringing the group's total stake to 5.0%.

Tang Capital Management and its affiliates have significantly increased their beneficial ownership in Aurinia Pharmaceuticals Inc., now holding 7.3% of the common shares after investing an additional $23.5 million.